View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 29, 2020

Novavax begins Phase III Covid-19 vaccine trial in the US and Mexico

Biotech firm Novavax has initiated a pivotal Phase III study of its Covid-19 vaccine candidate, NVX-CoV2373, in the US and Mexico.

Biotech firm Novavax has initiated a pivotal Phase III study of its Covid-19 vaccine candidate, NVX-CoV2373, in the US and Mexico.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

A full-length, prefusion spike protein, NVX-CoV2373 was created using Novavax’s recombinant nanoparticle technology along with its proprietary saponin-based Matrix-M adjuvant.

A single vaccine dose contains 5mcg of protein and 50mcg of adjuvant.

The vaccine is stable at 2-8°C and is transported in a ready-to-use liquid formulation that allows supply with the help of standard vaccine supply chain channels.

The Phase III PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19 trial (PREVENT-19) was initiated after data from Phase I/II studies showed that the vaccine triggered a robust immune response, produced highly neutralising antibodies against the virus, and was well-tolerated.

Novavax president and CEO Stanley Erck said: “With the Covid-19 pandemic raging around the globe, this trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world’s population.”

Being carried out with support from Operation Warp Speed partners, PREVENT-19 is an observer-blinded, placebo-controlled, randomised study to analyse the effectiveness, safety and immunogenicity of NVX-CoV2373 with Matrix-M versus placebo.

The trial will have around 30,000 adult participants who will be randomised in a 2:1 ratio to receive two intramuscular injections of NVX-CoV2373—administered 21 days apart—or placebo.

The primary and secondary endpoint of the trial will be the prevention of PCR-confirmed, symptomatic Covid-19 and moderate or severe disease, respectively.

Analysis of both the endpoints will be conducted at least seven days after the second dose.

Currently, Novavax is conducting a Phase III trial of the vaccine candidate in the UK, a Phase IIb safety and efficacy study in South Africa, and a Phase I/II trial in the US and Australia.

The company anticipates data from these trials to be available by the first quarter of next year.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena